High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia

• Published in: Leukemia Vol. 36; no. 6; pp. 1609 - 1618
• Main Authors: Ghia, Emanuela M., Rassenti, Laura Z., Choi, Michael Y., Quijada-Álamo, Miguel, Chu, Elvin, Widhopf, George F., Kipps, Thomas J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2022; Nature Publishing Group
• Subjects: 13/31; 38/91; 631/67/1059/2326; 631/67/1990/283/1895; 82/80; 96/109; Bcl-x protein; Bridged Bicyclo Compounds, Heterocyclic - pharmacology; Cancer Research; Chronic lymphocytic leukemia; Critical Care Medicine; Cytotoxicity; Gene expression; Genes; Hematology; Humans; Intensive; Internal Medicine; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Medicine; Medicine & Public Health; Minimal residual disease; Oncology; Patients; Receptor Tyrosine Kinase-like Orphan Receptors - genetics; Receptor Tyrosine Kinase-like Orphan Receptors - metabolism; Signal transduction; Signaling; Sulfonamides - pharmacology; Therapy; Wnt protein
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/s41375-022-01543-y

Although the BH3-mimetic venetoclax is highly cytotoxic for chronic lymphocytic leukemia (CLL) cells, some patients with CLL fail to clear minimal residual disease (MRD). We examined the CLL cells of seven such patients (CLL1-7) and found each had high-level expression of ROR1. By examining the CLL cells from such patients prior to therapy at SC1 and then more than 1 year later (Sample Collection 2 (SC2)), when they had progressive increases in MRD despite continued venetoclax therapy, we found the levels of ROR1 expressed on CLL cells at SC2 were significantly higher than that on CLL cells collected at SC1. At SC2, we also observed upregulation of genes induced by Wnt5a-induced ROR1 signaling, including BCL2L1 . Transduction of the CLL-cell-line MEC1 to express ROR1 enhanced expression of target genes induced by ROR1-signaling, increased expression of BCL-XL, and enhanced resistance to venetoclax, even in MEC1 made to express mutant forms of BCL2 , which are associated with venetoclax resistance. Treatment of primary CLL cells with Wnt5a also increased their resistance to venetoclax, an effect that could be inhibited by the anti-ROR1 mAb (UC-961, zilovertamab). Collectively, these studies indicate that Wnt5a-induced ROR1-signaling can enhance resistance to venetoclax therapy.